Navigation Links
Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plc announced today the positive results of studies of the investigational medication guanfacine extended release (GXR, previously referred to as SPD503), a selective alpha-2A-adrenoceptor agonist. These data from two short-term phase III placebo-controlled studies and two long-term phase III open-label studies, presented at the 2007 American Psychiatric Association (APA) annual meeting, demonstrated that GXR significantly improved all core symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 17 years.

"Guanfacine extended release, the first selective alpha-2A-adrenoceptor agonist to be tested in well-controlled studies as a treatment for ADHD, holds potential based on the significant improvements in ADHD symptoms documented in four studies of this investigational drug," stated co-author Joseph Biederman, M.D., lead investigator, chief of clinical and research program in pediatric psychopharmacology at Massachusetts General Hospital and professor of psychiatry at Harvard Medical School. "Moreover, these data presented at this medical conference add evidence that GXR when dosed once daily may continue to control children's ADHD symptoms for up to 24 months."

GXR, a nonstimulant, is not a controlled substance and does not appear to have a mechanism for potential abuse or dependence. Shire submitted a New Drug Application (NDA) for GXR on August 24, 2006, which is currently under FDA review. The NDA provided data on GXR 1 mg to 4 mg taken once daily for the treatment of children and adolescents with ADHD.

GXR Yielded Significant Reductions in ADHD-RS-IV Scores in Two Short-Term Trials

Results from two short-term, double-blind, randomized phase III clinical trials presented at this medical conference, demonstrated that GXR significantly controlled all core symptoms of ADHD, including inattention, hyperac
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/13/2014)... , July 13, 2014 ... in Tokio veranstalteten ... firmenseitigen Bemühungen zur Neuausrichtung seines Forschungsrahmenprogramms. Die ... Überblick über die fortgeschrittenen klinischen Programme und ... Ziel der Tagung bestand darin, aktuelle Meldungen ...
(Date:7/13/2014)... , July 13, 2014  Eli Lilly ... announced results from its non-clinical study in genetically ... version of the beta-amyloid antibody N3pG and beta-secretase ... therapy was more effective in removing clumps of ... that is thought to lead to Alzheimer,s disease ...
(Date:7/11/2014)... 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced ... for use in portable vaporizers, which contains CBD, ... in cannabis, cannabidiol offers consumers a THC-free product ... other vaporizer technology. Photo - ... 483 different compounds which are currently known, two ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... Md., Sept. 2 Celsion Corporation (Nasdaq: ... today that it has been awarded a competitive ... grant from the National Institutes of Health (NIH), ... Liposomes for Cancer".  This funding will support the ...
... Ascension Orthopedics, Inc., the world leader in ... the TITAN™ Modular Total Shoulder System. This newly ... solutions for shoulder arthroplasty with one implant system. ... was developed in collaboration with Joseph Abboud, M.D, ...
Cached Medicine Technology:Celsion Receives SBIR Grant To Expand Its Technology Platform 2Celsion Receives SBIR Grant To Expand Its Technology Platform 3Ascension Orthopedics Receives FDA Approval for TITAN™ Modular Total Shoulder System 2
(Date:7/13/2014)... editorial published today in The Lancet Neurology ... consideration the long term neurological problems that repeated ... most common form of sports-related traumatic brain injury ... may include dementia, amyotrophic lateral sclerosis, and other ... is perhaps more concerning, is that even when ...
(Date:7/13/2014)... identifies a novel genetic and molecular pathway ... opening up potential new therapeutic strategies for an ... is a chronic inflammatory disorder of the esophagus. ... certain foods and an over-accumulation in the esophagus ... the body,s immune system). EoE can cause a ...
(Date:7/13/2014)... July 13, 2014 The North American water ... in 2013 to $5,450 million by 2018, at a CAGR ... market is expanding at a rapid pace in North America. ... tightening laws on water & wastewater storage and collection, and ... The market is expanding at a healthy rate in Canada, ...
(Date:7/13/2014)... July 13, 2014 According to ... and Computing Market by Component (processor, GPU, DSP, ... MDA, Medical), and Geography - Forecast and Analysis ... Mobile Processing & Computing Market is expected to ... CAGR of 20.75% from 2014 to 2020. , ...
(Date:7/13/2014)... WA (PRWEB) July 13, 2014 Athletes ... longer recovery period from concussions, according to research presented ... ( AOSSM ) Annual Meeting. The research marks the ... concussion based on the known physical events that occur ... patients with a long allele in the (GT)n genotype ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... Programs for Eating Disorders,( http://www.remudaranch.com ), the nation,s ... surround the nation,s obsession,with dieting. As the dieting ... Americans continue to lose and gain weight in ... cycling may elevate blood pressure,reduce good cholesterol, deplete ...
... Medical Technologies,Inc., an innovator of endovascular treatments for ... another patent for its,Pathway PV(TM) Atherectomy System. The ... related to Pathway Medical,s innovative,atherectomy system, which is ... the legs. Pathway Medical has a total of ...
... women to enjoy casual sex just as men always had. ... the UK, the negative feelings reported by women after one-night ... sexual encounters. Her findings (1) are published online in ... , Men are more likely to reproduce and therefore to ...
... hurt. It was like [their father] had met some gal ... she wanted all his money. I felt they didn,t give ... still hurts.", --Remarried wife of 12 years, caring for husband ... Mich.---Late-life remarriage complicates caring for an ailing spouse, according to ...
... June 25 Hologic, Inc.,(Nasdaq: HOLX ) today ... the waiting period under the Hart-Scott-Rodino,Antitrust Improvements Act of ... in connection with Hologic,s previously announced tender offer for,all ... Third Wave,Technologies, Inc. (Nasdaq: TWTI ). The early ...
... looking for qualified candidates and tens of thousands of jobs being created ... graduates and despite the layoff announcements that tend to shock the average ... ... number of available jobs in health care continued to rise through the ...
Cached Medicine News:Health News:Leading Eating Disorder Treatment Center Identifies Popular Diet Myths 2Health News:Leading Eating Disorder Treatment Center Identifies Popular Diet Myths 3Health News:Was it good for you too? 2Health News:Late-life remarriage: Stepfamilies make caring more complex 2Health News:Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer 2Health News:The MedZilla Report: May 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: May 2008 Employment Outlook for Biotech/Pharma/Health 3
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... The Retinal Acuity Meter (RAM) is the ... to accurately predict RETINAL ACUITY in eyes with ... hand-held, battery operated, and can test each eye ... Optics, Inc. and tested at Columbia University in ...
... The Hoffmann® II Hybrid External Fixation ... next generation in hybrid fixation. It ... surgeons and is designed to offer ... exclusive patented Hoffmann® snap-fit technology. , ...
... add individual components for individual indications. XCaliber ... Made of an innovative composite plastic material, ... much lighter. This means it's easier to ... for the patient. ,Come pre-assembled, packaged sterile, ...
Medicine Products: